Modulation of control mechanisms of dopamine-induced apoptosis--a future approach to the treatment of Parkinson's disease?
The cause for the progressive and selective degeneration of the dopaminergic (DA) nigrostriatal neurons in Parkinson's disease (PD) is still unknown. We suggest a novel approach, that links this neuronal degenerative process to inappropriate triggering of apoptosis, an active, controlled program of cellular self destruction, by excess oxidative stress mediated by DA metabolism. In support of this concept, we found that DA, the endogenous neurotransmitter, is capable of initiating apoptosis in cultured, postmitotic chick sympathetic neurons, an observation further extended to other cellular systems (PC-12 cells, cerebellar granular cells, thymocytes, splenocytes). In comparing the relative apoptosis-triggering potency of other mononamine neurotransmitters, DA was found to be the most active, whereas norepinephrine and serotonin had a moderate and a mild effects, respectively. This grading can be correlated with the relative involvement of the relevant neuronal systems (i.e., substantia nigra, locus ceruleus and raphe nuclei) in PD. We therefore hypothesize that neuronal degeneration in PD may be caused, at least in part, by a failure, either inherited or acquired, in cellular control systems of apoptosis, that may normally restrain the lethal potential of these endogenous neuro-transmitters and their potentially-toxic oxidation products. We therefore point at apoptosis-control systems as a critical scene of events, where the fate of nigrostriatal neurons is ultimately determined, and whose modulation may yield attenuation of the neuronal degenerative process. In support of this concept, we found that vector-driven stable expression of the proto-oncogene bcl-2, an inhibitor of apoptosis, can exert powerful cellular protection against DA toxicity in rat pheochromocytoma PC-12 cells. Furthermore, cell extracts from bcl-2-expressing cells were found to markedly inhibit in vitro oxidation of DA and production of DA-melanin. We also found that expression of bcl-2 can inhibit the decrease in intracellular reduced thiol (-SH) groups which we observed following exposure to DA. Research of the bcl-2 system and associated control mechanisms of apoptosis, possibly acting in association with intra-cellular anti-oxidant pathways, may therefore lead to novel therapeutic approaches for neuroprotection in PD.
Ziv
I
I
Department of Neurology, Beilinson Medical Center, Petah-Tiqva, Israel.
Offen
D
D
Barzilai
A
A
Haviv
R
R
Stein
R
R
Zilkha-Falb
R
R
Shirvan
A
A
Melamed
E
E
D000818:Animals; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D003342:Corpus Striatum / Q000473:pathology*; D004298:Dopamine / Q000502:physiology*; D006801:Humans; D009410:Nerve Degeneration; D009474:Neurons / Q000473:pathology*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000473:pathology*; D000090063:Proto-Oncogene Mas; D051381:Rats; D013378:Substantia Nigra / Q000473:pathology*
D000978:Antiparkinson Agents; C000715470:MAS1 protein, human; D000090063:Proto-Oncogene Mas; D004298:Dopamine